Deficient T H-1 responses from TNF-a-matured and α-CD40-matured dendritic cells

Journal of Immunotherapy

Volumn 31, Issue 2, 2008, Pages 157-165

  Decker, William K ^a   Li, Sufang ^a   Xing, Dongxia ^a   Robinson, Simon N ^a   Yang, Hong ^a   Steiner, David ^a   Komanduri, Krishna V ^a   Bollard, Catherine M ^b   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Dendritic cell; Maturation; T H 1 response

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; DINOPROSTONE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44949245014     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31815eb0df     Document Type: Article

References (28)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
2. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:873-886.
3. Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transplant. 2006;12:113-125.
4. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162:168-175.
5. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
6. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocytes-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(suppl 4):A8-A22.
7. de Vries IJM, Krooshoop DJEB, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17.
8. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
9. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173-180.
10. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
11. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-3807.
12. Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother. 2004;53:651-658.
13. Decker WK, Xing D, Li S, et al. Double loading of dendritic cell MHC Class I and MHC Class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006;24:3203-3216.
14. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
15. Bennett SRM, Carbone FR, Karamalis F, et al. Help for cytotoxic- T-cell responses is mediated by CD40 signalling. Nature. 1998;393: 478-480.
16. Scheinecker C, Machold KP, Majdic O, et al. Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol. 1998;161:3966-3973.
17. Scholler N, Hayden-Ledbetter M, Dahlin A, et al. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol. 2002;168:2599-2602.
18. Dannull J, Nair S, Su Z, et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood. 2005;105:3206-3213.
19. Takahashi A, Kono K, Ichihara F, et al. Vascular epithelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not proinflammatory cytokines. Cancer Immunol Immunother. 2004;53:543-550.
20. Curti A, Isidori A, Ferri E, et al. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma. 2004;45:1419-1428.
21. Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170:4069-4076.
22. Hunter TB, Alsarraj M, Gladue RP, et al. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumor T-cell responses in an in vitro mixed autologous tumor cell/lymph node cell model. Scand J Immunol. 2007;65:479-486.
23. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180: 1263-1272.
24. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003;21: 3826-3835.
25. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B-cells. J Immunol. 1994;152:2675-2685.
26. Romagnani S. Regulation of the T-cell response. Clin Exp Allergy. 2006;36:1357-1366.
27. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29:545-557.
28. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother. 2005;28: 505-516.